eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Four versus six cycles of cyclophosphamide/doxorubicin or paclitaxel in adjuvant breast cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
    Antineoplastic combined chemotherapy
  5. Resource Description
    It is not yet known whether giving cyclophosphamide together with doxorubicin is more effective than giving paclitaxel alone in treating breast cancer. This randomized phase III trial is studying cyclophosphamide and doxorubicin to see how well they work compared to paclitaxel in treating women with invasive breast cancer.
  6. Additional Name
    Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
  7. Contact
    Berenberg, Jeffrey
  8. PI
    Berenberg, Jeffrey
  9. Topic
    breast cancer
  10. Study Population
    Women 18 years and older with Histologically confirmed invasive carcinoma of the breast with 0-3 positive axillary lymph nodes
  11. Funded by
    Cancer Trials Support Unit
  12. Phase
    Phase 3 clinical trial
  13. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016